Pfizer and French biotech Valneva are aiming to avoid previous pitfalls in developing a new vaccine to protect both adults and kids as young as 5 from Lyme disease.

While the EU is still getting and distributing vaccine — unlike much of the world — it has so far been left in the U.K.'s rearview mirror.